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Abstract
Background: Worldwide, the use of prostate specific antigen (PSA) testing as a screen for
prostate cancer is contentious. Whilst there is no National UK Screening programme, many men
undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the
awareness surrounding the Department of Health (DoH) PSA guidelines.
Methods: Urologists were sent a questionnaire regarding PSA cut-off values.
Results:  Of the 733 urologists eligible to participate in this study 346 returned completed
questionnaires giving a response rate of 47%. The most commonly generally used age-related PSA
cut-off values (36% of respondents) are – 3.5 ng/ml for 50 – 59 year olds, 4.5 ng/ml for 60 – 69 year
olds and 6.5 ng/ml for over 70 year olds. Two-thirds (58%, 200/346) of respondents were aware
of the DoH PSA guidelines but only 20% (n = 69/346) follow these guidelines. The majority of
respondents (68%, n = 234/346) used higher PSA cut-offs than recommended by the DoH. The
level of compliance showed marked regional variation with a range from 7% to 44% (median 19%).
In addition, it was apparent that lower PSA cut-off values were used in private practice as opposed
to the National Health Service.
Conclusion: A nationwide lack of agreement on PSA cut-off values may generate a variable
standard of care both regionally and in NHS versus private practice. Generally, higher PSA cut-off
values are being used than recommended by the DoH guidance.
Background
Prostate cancer is the most common male cancer, with
nearly 32,000 men diagnosed in the UK each year [1].
Unlike breast and cervical cancer, its female counterparts,
there is no national United Kingdom (UK) screening pro-
gramme for prostate cancer. However at present oppor-
tunistic screening is occurring, with many physicians
using the serum Prostate-Specific Antigen (PSA) test.
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PSA, also known as human kallikrein 2, is produced by
the luminal prostatic cells which line prostatic acini. PSA
is responsible for liquefying semen and hence has a major
role in fertility [2]. It is possible to detect PSA in small
amounts in the serum of healthy males and this level
increases in prostate cancer [3]. However, whilst PSA is tis-
sue specific an increase in circulating levels is not defini-
tively linked to tumour development. Urethral
instrumentation, urinary infection, prostatitis, urinary
retention, ejaculation and benign prostatic hypertrophy
all raise serum PSA levels [3]. The PSA serum test was ini-
tially used as a sign of recurrent disease following radical
prostatectomy or radiotherapy for prostate cancer, but
came into mainstream usage as an diagnostic test in the
1980s [4].
Based upon a cut-off level of 4 ng/ml, the standard serum
PSA test has a sensitivity of approximately 90% and a spe-
cificity of approximately 40% [5]. However, these values
change depending upon the specified PSA cut-off level.
The high false positive rate leads to a large number of men
undergoing further investigations, which are unnecessary,
invasive and raise anxiety. False negative tests also occur
and serve to give false reassurance, as some prostate cancer
will be missed.
There is no worldwide consensus on prostate cancer
screening. There are several studies to date that have
looked at the benefit of screening for prostate cancer. An
observational study from Tyrol, Austria [6] reported on
the geographical differences observed between Tyrol,
where PSA testing had been freely available since 1993,
and the rest of Austria, where it hadn't. The study showed
a marked decline in prostate cancer mortality detected in
Tyrol as compared to the rest of Austria. The European
Randomised Study of Screening for Prostate Cancer
(ERSPC) is still underway, however preliminary results
suggest that screen detected prostate cancer has more
favourable prognostic indicators that non-screen detected
prostate cancer, but as yet no mortality advantage to
screening has been shown [7].
The USA is the only country currently to have a national
prostate cancer screening programme. The American Can-
cer Society and American Urological Association recom-
mend an annual PSA test for all men aged 50 or over with
an estimated 10 year life expectancy or more [8]. A PSA
cut-off value of 4.0 ng/ml is used [9].
Despite not having a National Screening Programme in
the UK, the Department of Health has released guidelines
in the form of the Prostate Cancer Risk Management Pro-
gramme for General Practitioners involved in using the
PSA test [10]. The Prostate Cancer Risk Management Pro-
gramme was produced by the National Health Service
(NHS) Cancer Screening Programme and Cancer Research
UK under advice from a multi-disciplinary expert group
set up by the Department of Health. This recommended
that men concerned about prostate cancer should be
offered a PSA test but only after fully informed consent
following discussion of the limitations of the test. The PSA
cut-off levels that they suggest, either for referral to a urol-
ogist or for consideration of further investigation, are
shown in Table 1.
This study was therefore designed to investigate the usage
of PSA cut-off values amongst Urologists in the UK and to
determine the awareness of the Department of Health PSA
guidelines. This was investigated in Consultants working
in both the National Health Service (the free UK Govern-
ment led service) and/or the private sector.
Methods
Study design
We conducted a questionnaire-based study on the usage
of PSA cut-off values. Self-administered questionnaires
(see additional file 1) were sent to urologists across Eng-
land, Wales and Northern Ireland. Urologists in Scotland
were excluded from this study as they have a separate
Department of Health.
Two rounds of questionnaires were sent to the same group
of urologists, the same exclusion criteria (outlined in
detail below) were used for both rounds. Questionnaires
were initially e-mailed to potential participants and non-
responders were sent a subsequent postal and repeat e-
mail questionnaire.
In the first round we contacted 961 urologists thought eli-
gible to take part in this study – of these 178 initially
replied (response rate = 19%). In the second round a fur-
ther 228 urologists were found to be ineligible for the
study based upon exclusion criteria outlined below. This
left a total of 733 urologists eligible to take part – 178 had
originally replied and a further 168 replied in the second
round, thus giving a total number of 346 urologists who
replied. Response rate was therefore increased to 346/733
= 47%.
The primary outcome measures were levels of the PSA ref-
erence values used and awareness of the Department of
Health PSA guidelines. Secondary outcome measures
included the use of additional PSA-linked investigations
and an opinion on the current guidelines and implemen-
tation of a national PSA screening programme.
Ethical approval was not needed for this study.BMC Urology 2008, 8:17 http://www.biomedcentral.com/1471-2490/8/17
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Participants
733 urologists were identified from the British Associa-
tion of Urologists (BAUS) Members Handbook as being
eligible for this study based upon their membership crite-
ria. Only full members, junior members and associate
urologist specialist members were included in this study.
Specific exclusion criteria included senior membership of
BAUS, overseas membership, un-contactable urologists
(e.g. those not providing an address), and urologists not
currently participating in oncological practice (e.g. paedi-
atric urologists).
Statistical analysis
Data has been analysed using Graphpad Prism version 5.0
software USA, statistical analysis used the unpaired t test
and Fishers exact.
Results
Characteristics of respondents
Of the 733 urologists eligible to participate in this study
346 returned completed questionnaires giving a response
rate of 47%. The majority of respondents were consultants
(193/346 – 56%) with the remaining 44% being com-
posed of registrars and non-consultant career grades. Of
the 346 respondents 202 (58%) treated NHS patients
only, 2 (0.01%) treated private patients only and 142
(41%) treated both patient groups. Participants were
divided into 10 regions, the number of responses per
region were: Eastern (A) – 26, London (B) – 62, North
West (C) – 41, Northern and Yorkshire (D) – 42, South
East (E) – 33, South West (F) – 50, Trent (G) – 27, West
Midlands (H) – 35, Wales (I) – 12, and Northern Ireland
(J) – 18.
Usage of age-related PSA cut-off values
In each of the three age groups a wide range of PSA refer-
ence values were being used (50–59 year olds: 2.0–5.0 ng/
ml; 60–69 year olds: 3.0–6.5 ng/ml; 70–79 year olds: 3.5–
7.5 ng/ml). The most commonly used (36% of respond-
ents) set of age-related PSA cut-off values was 2.5 ng/ml
for 40 – 49 year olds, 3.5 ng/ml for 50 – 59 year olds, 4.5
ng/ml for 60 – 69 year olds and 6.5 ng/ml for 70–79 year
olds. The Department of Health uses age-related PSA cut-
offs in its guidelines, as shown in Table 1. 20% (n = 69/
346) of respondents followed the Department of Health
PSA age-related cut-off values in their current clinical prac-
tice. Age-matched PSA cut-off values for NHS versus pri-
vate practice were compared, showing 20% (68/344) vs
26% (38/144), respectively, of urologists using the DoH
PSA guidelines. When this was further investigated it was
clear that most respondents, in both NHS and private
practice, were using values higher than those recom-
mended by the Department of Health (Figure 1). The
median PSA cut-off values for ages 60–69 and 70–79 were
higher in NHS (4.5 and 6.0 ng/ml respectively) compared
to private (4.0 and 5.5, respectively) practice (Table 1).
When direct comparison of NHS and private age-related
PSA reference values was made for the 142 respondents
who saw both groups of patients we found that 10% (n =
14/142) used lower age-related reference values in their
private versus their NHS practice.
Interestingly, there were clear regional differences across
the UK (Figure 2). In the regions, between 7% (2/27 –
region G) and 44% (22/50 – region F) of Urologists were
following the DoH PSA guidelines.
Use of PSA-Related Tests
Other PSA-related test procedures, such as PSA density,
velocity, ratios of free to total PSA and analysis of PSA iso-
forms, have been suggested to enhance the sensitivity and
clinical relevance of the standard serum PSA test. The
standard serum PSA test alone was used by one in five
(18%, n = 62/144) of respondents for NHS practice,
whilst one in three (35%, n = 51/144) of respondents
relied solely on this test for private practice. The most
common additional test used by respondents was PSA
velocity, which was used by 75% (n = 255/342) of
respondents in NHS practice and 82% (n = 118/144) of
respondents in their private practice (Table 2).
Awareness of, and agreement with the Department of 
Health Guidelines
Despite the widespread use of PSA testing in urological
practice and the ready availability of the Department of
Health PSA Guidelines on the internet http://www.can
cerscreening.nhs.uk/prostate/index.html and elsewhere,
less than two-thirds (58%, 200/346) of respondents were
aware of the recommended PSA cut-off values. Of those
respondents who were aware of the guidelines: 57% (114/
200) agreed with the values cited; 24% (47/200) disa-
greed; 12% (24/200) offered no opinion, while 7% did
not respond to the question.
A majority of respondents (59%, n = 205/346) believe
that there should not be a National screening programme
for prostate cancer based upon the Department of Health
serum PSA guidelines. The most common reason for this,
cited by 30 of the 81 (37%) urologists commenting on
this in the free text response box provided, was a lack of
evidence-based medicine supporting the case for PSA
screening.
Discussion
The principal finding of this study is that, in the UK, there
is a widespread variation in the application of PSA cut-off
values among urologists, which may be leading to an ine-
quality in men's healthcare related to PSA testing.
Although just under two-thirds of urologists participating
in this study were aware of the Department of Health PSABMC Urology 2008, 8:17 http://www.biomedcentral.com/1471-2490/8/17
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Illustration of range of age-specific prostate specific antigen cut-off values and the number of respondents using them. Figure 1
Illustration of range of age-specific prostate specific antigen cut-off values and the number of respondents 
using them. Black arrows  indicate Department of Health guidelines.
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age-related guidelines, less than a third used them in eve-
ryday clinical practice. Interestingly, research has shown
that only 56% of General Practitioner (GP) partners are
aware of the PSA guidelines [11].
Whilst these guidelines were intended for GPs, they have
also been sent to many urologists within the United King-
dom. The PSA guidelines were formed because of the
dilemma faced by all medical staff dealing with asympto-
matic men who request or have a PSA test, in that there are
many pitfalls associated with the sensitivity and specificity
of the PSA test. For this reason there is no screening pro-
gramme within the UK. However opportunistic testing
occurs both in general practice and within secondary care
by urologists and other physicians. Whilst further research
is awaited the government has attempted to guide practice
in a practical manner via these PSA guidelines.
It is important to raise awareness of how the PSA test
should be correctly utilised not just amongst GPs, but
amongst all of the medical profession.
The transition of patients between primary care and sec-
ondary care via referral pathways is much more efficient if
both Urologists and GPs are aware of the referral guide-
lines. Therefore for this point alone it is important for
urologists to be aware of the DoH PSA guidelines.
Once a patient arrives in the secondary care setting after
being referred with an abnormal PSA result a decision
must be made as to whether the patient needs to undergo
a prostate biopsy. When making this decision, the urolo-
gist takes not only the PSA result into account, but also
urological symptoms, family history and digital rectal
examination. This is a complex decision, involving discus-
sion with the patient regarding the sensitivity and specifi-
city of a PSA test, together with morbidity involved in a
prostate biopsy. However, when making the final decision
of when to biopsy – whether the PSA is within the "nor-
mal" levels, and what these levels are perceived to be plays
a large role. Many laboratories within the UK are using the
DoH referral guidelines as PSA cut-off values, which will
in turn be used by urologists as a guide to normality levels,
and thus will aid in the decision making process of
whether to biopsy a man.
This lack of compliance with the Department of Health
PSA guidelines is likely to be due to the paucity of evi-
dence supporting the recommended age-related PSA cut-
offs, and this was commented on by a number of partici-
pants.
The only published report suggesting PSA age-related cut-
offs is a study by Oesterling et al. in 1993 [12]. This pop-
ulation-based study in Olmstead County, USA, recruited
Percentage of urologists using Department of Health prostate specific antigen guidelines.  Figure 2
Percentage of urologists using Department of Health prostate specific antigen guidelines. Split by region (A - J).
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2119 men between the ages of 40–79, to investigate the
natural history of benign prostatic hyperplasia. A quarter
of these men were randomly chosen to undergo a PSA test,
a digital rectal examination and a Trans-Rectal Ultrasound
(TRUS) guided prostate biopsy. PSA values for the 88% of
men with no evidence of prostate cancer were evaluated.
On this basis, PSA cut-offs were suggested of 2.5 ng/ml for
40 – 49 year olds, 3.5 ng/ml for 50 – 59 year olds, 4.5 ng/
ml for 60 – 69 year olds and 6.5 ng/ml for 70–79 year olds
based upon the serum PSA 95th percentiles. Interestingly
this was the most widely used set of PSA cut-offs in our
study, being used by 36% of respondents.
Wide regional differences in the age-related PSA cut-off
values may potentially lead to subsequent regional varia-
tion in the likelihood of men undergoing further invasive
investigations, such as TRUS guided prostatic biopsies. In
addition, when PSA cut-off values are compared between
urologists treating patients in the NHS and the private sec-
tor it is clear that lower values are being used in private
healthcare. Hence patients being treated by the NHS are
less likely to have further investigations which may poten-
tially result in the later detection of prostate cancer in a
small percentage of these patients.
An interesting observation from our study is the wide
range of PSA cut-off values being used for each age group.
By using data from the Prostate Cancer Prevention Trial
(PCPT) placebo group [13], we are able to extrapolate the
percentage likelihood of a man being diagnosed with
prostate cancer as indicated by their PSA value. For exam-
ple, in our study a man in the 50 – 59 year age group has
a PSA cut-off value ranging from 2.0 to 5.0 ng/ml. Using
PCPT data, a PSA cut-off of 5.0 ng/ml rather than 2.0 ng/
ml more than doubles the likelihood of having prostate
cancer detected at biopsy. Perhaps more worryingly, in the
PCPT study the risk of detecting high grade prostate can-
cers increases threefold (5.7% to 14.6%) when a PSA cut-
off of 5.0 ng/ml rather than 2.0 ng/ml is used. Therefore,
the use of higher PSA cut-off values may result in men
with high grade prostate cancers being detected later.
The response rate for this study was 47% which is compa-
rable to other questionnaire based studies of urologists.
Survey-based studies have the inherent problem of selec-
tion bias and the resultant effect on conclusions is difficult
to determine. Any comparisons that are made in our
results may well be affected by the lack of response from
53% of urologists, and bias may well have been intro-
duced because of this. Particularly in the comparison
between regions, as relatively small numbers are being
compared, and we are unable to assess where the 53% of
urologists who didn't reply are based.
However, it could be argued that the individuals who are
more likely to participate in a survey such as this are the
enthusiastic group of urologists who are more likely to be
aware of the existence of Department of Health guidelines
and current practices involving PSA cut-offs. Therefore
this would suggest that the group who didn't reply actu-
ally may have more variable use of age-related PSA cut-
offs than our study has quoted.
Interestingly Meyer et al. [14] investigated the uniformity
of prostate cancer guidelines by comparing the guidelines
provided by the British Association of Urological Sur-
geons, European Association of Urology and American
Urological Association and also found that there was a
general lack of uniformity in the management of prostate
cancer.
There remain several unanswered questions regarding the
natural history of, and best treatment for, prostate cancer
and a number of large trials investigating such questions
are underway (The United States Prostate, Lung, Colon
and Ovary Screening Trial, The European Randomised
Study of Screening for Prostate Cancer and The United
Kingdom PROstate Testing for Cancer and Treatment
study). The results of such trials are likely to initiate dis-
cussion regarding prostate cancer screening and the role of
PSA in this. An important implication of the results pre-
sented here is that they highlight a lack of discussion, both
within the urological community and between urologists
and the Department of Health, regarding current PSA cut-
off guidelines. We hope that avenues will be explored to
improve discussion and hence obtain widespread agree-
ment on any future PSA cut-off guidelines. UK men have
a right to receive a standardised level of care throughout
the country.
Conclusion
The principal finding is that most urologists surveyed use
evidence-based cut-offs, which however are not in accord-
ance with the guidelines suggested by the DoH. A signifi-
cant proportion of urologists surveyed appear to be
unaware of the DoH guidelines. There is, therefore, a wide
range of age related PSA cut-offs being used throughout
the United Kingdom, and differences are also apparent
between the levels used in the NHS and private practice.
Thus creating an inequality in the healthcare received by
men throughout the country.
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